Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
ProQR (PRQR)
NASDAQ:PRQR
PRQR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.61 - $4.62
Previous CloseN/A
Volume75.97K
Average Volume (3M)329.34K
Market Cap
$266.27M
Enterprise Value$66.50M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Feb 26, 2025EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding103,203,735
10 Day Avg. Volume253,117
30 Day Avg. Volume329,342
Standard Deviation0.35
R-Squared0.00141
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)21.84
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$9.60Price Target Upside272.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
ProQR News
PremiumCompany Announcements
ProQR Secures $8.1 Million for Rett Syndrome RNA Therapy
PremiumCompany Announcements
ProQR Strengthens RNA Editing Team with Key Appointment
PremiumCompany Announcements
ProQR Highlights RNA Innovations in Upcoming Event---
Bulls Say, Bears Say
Bulls Say
FundingThe Company has expanded its focus on Rett syndrome, supported by an additional $8.1 million in funding from the Rett Syndrome Research Trust.
Partnership And CollaborationsPartnership with Eli Lilly underscores platform value and opens the door for milestone payments down the road.
ValuationProQR is seen as an attractive opportunity for investors as it trades at a discount to RNA-editing peers and is differentiated by pursuing novel targets in areas of high unmet need.
Bears Say
Clinical Program DelaysThe timing for AX-1412, targeting cardiovascular disease, has also been pushed out.
Program UncertaintiesOther programs in cardiovascular disease and MASH are moving forward and the Company anticipates bringing forward 2 clinical programs per year.
Timeline DelaysThe timing for the Company's lead ADAR therapeutic, AX-0810, to enter the clinic has been pushed out 2 quarters.
---
Ownership Overview
―
Insiders
1.49% Mutual Funds
32.46% Other Institutional Investors
65.65% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PRQR FAQ
What was ProQR’s price range in the past 12 months?
ProQR lowest stock price was $1.61 and its highest was $4.62 in the past 12 months.
What is ProQR’s market cap?
ProQR’s market cap is $266.27M.
When is ProQR’s upcoming earnings report date?
ProQR’s upcoming earnings report date is Feb 26, 2025 which is in 4 days.
How were ProQR’s earnings last quarter?
ProQR released its earnings results on Nov 07, 2024. The company reported -$0.104 earnings per share for the quarter, beating the consensus estimate of -$0.11 by $0.006.
Is ProQR overvalued?
According to Wall Street analysts ProQR’s price is currently Undervalued.
Does ProQR pay dividends?
ProQR does not currently pay dividends.
What is ProQR’s EPS estimate?
ProQR’s EPS estimate is -0.1.
How many shares outstanding does ProQR have?
ProQR has 103,203,735 shares outstanding.
What happened to ProQR’s price movement after its last earnings report?
ProQR reported an EPS of -$0.104 in its last earnings report, beating expectations of -$0.11. Following the earnings report the stock price went down -1.923%.
Which hedge fund is a major shareholder of ProQR?
Currently, no hedge funds are holding shares in PRQR
---
ProQR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.60 (272.09% Upside)
$9.60 (272.09% Upside)
Hedge Fund Trend
Decreased
By 97.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 3.1%
Last 30 Days ▲ 1.6%
Last 30 Days ▲ 1.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
35.78%
12-Months-Change
Fundamentals
Return on Equity
-67.62%
Trailing 12-Months
Asset Growth
-20.70%
Trailing 12-Months
Company Description
ProQR
ProQR Therapeutics NV operates as a biopharmaceutical company, which engages in the discovery and development of Ribonucleic Acid RNA based therapeutics for the treatment of genetic disorders. Its initial focus is on the development of a disease-modifying therapy for the treatment of cystic fibrosis. The company was founded by Daniel de Boer, Gerard Platenburg, Henri Termeer and Dinko Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands.
---
PRQR Stock 12 Month Forecast
Average Price Target
$9.60
▲(272.09% Upside)
Technical Analysis
Ionis Pharmaceuticals
―
Sarepta Therapeutics
―
PTC Therapeutics
―
RegenXBio
―
Editas Medicine
―
Best Analysts Covering PRQR
1 Year
1 Year Success Rate
13/25 ratings generated profit
1 Year Average Return
-7.63%
reiterated a buy rating last month
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 52.00% of your transactions generating a profit, with an average return of -7.63% per trade.
---